Business
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th
MOUNTAIN VIEW, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will be participating at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum, to be held on November 20, 2025. Mr. Bagai will share an update on
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIkpg_5WC5Ht6PAvrhd3Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will be participating at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum, to be held on November 20, 2025.","length":473,"tagName":"p"},{"type":"text","content":"Mr. Bagai will share an update on RenovoRx’s commercialization progress, driven by strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. He will also highlight the latest developments from the Company’s ongoing Phase III TIGeR-PaC clinical trial, evaluating RenovoRx’s novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath known as IAG) in locally advanced pancreatic cancer (LAPC). In addition, Mr. Bagai will discuss the Company’s recently launched post-marketing observational registry study designed to evaluate the long-term safety signals and survival outcomes for patients diagnosed with solid tumors receiving cancer treatment delivered via RenovoCath.","length":802,"tagName":"p"},{"type":"text","content":"Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum Details:Date: November 20, 2025Location: Westin NY Grand Central, New York, NY","length":161,"tagName":"p"},{"type":"text","content":"To schedule a one-on-one investor meeting with Mr. Bagai, please contact your Canaccord Genuity representative or KCSA Strategic Communications at [email protected].","length":165,"tagName":"p"},{"type":"text","content":"About RenovoRx, Inc.RenovoRx,...